LeMaitre Vascular (NASDAQ:LMAT) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

LeMaitre Vascular (NASDAQ:LMAT) released its earnings results on Wednesday. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04), FiscalAI reports. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. During the same quarter in the previous year, the company earned $0.75 earnings per share. The firm’s revenue was up 11.3% on a year-over-year basis.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q3 organic sales grew 12%, driven by 7% pricing and 5% unit growth, with gains across products and regions. LeMaitre reiterated 11% full-year organic growth guidance and expects adjusted EPS to rise 18% to $2.80.
• The B. Braun acquisition adds vascular grafts and other devices with $9.4 million in 2025 sales, but the commercial transition is expected to take 18–24 months. LeMaitre warned of potential customer losses during the transition and expects to record only about $150,000 of related revenue in Q4.
• RestoreFlow revenue grew 34%, including 65% growth in cardiac tissue, but quality-control processing constraints are limiting how much product the company can release and sell. Management said the bottleneck may persist for a while as it adds resources to address it.
• Full-year operating-margin guidance is 27%, with the outlook reduced by about $1.4 million, reflecting the FAS-TIP inventory reserve, faster sales-force and infrastructure investment, RestoreFlow transfer costs, and foreign-exchange pressure. Q3 operating expenses rose 18% year over year.

LeMaitre Vascular Trading Up 9.1%

NASDAQ LMAT traded up $7.32 during mid-day trading on Wednesday, hitting $87.92. The company’s stock had a trading volume of 514,878 shares, compared to its average volume of 271,336. The firm has a market capitalization of $2.01 billion, a P/E ratio of 30.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. LeMaitre Vascular has a 52-week low of $78.22 and a 52-week high of $118.01. The stock’s fifty day simple moving average is $81.38 and its two-hundred day simple moving average is $94.16.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Wells Fargo & Company decreased their price target on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 5th. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Finally, Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.